Pathways responsible for the tumor-protective function of TAMs against chemotherapy
| Tumor | Drug | Mechanism | Reference |
| Mammary, carcinoma | PTX | CSF1-dependent increased recruitment of TAMs | DeNardo et al., 2011 |
| Mammary, carcinoma | PTX, doxorubicin, etoposide | Increased protease activity | Shree et al., 2011 |
| Cervical, carcinoma | Platinum | Protumor polarization of TAMs | Dijkgraaf et al., 2013 |
| EL-4 lymphoma and other transplanted solid tumors | Gemcitabine + 5-FU | Skewed Th17 response | Bruchard et al., 2013 |
| Pancreatic, carcinoma | Gemcitabine | Induction of drug-metabolizing enzyme | Weizman et al., 2014 |
| Lung, colon, pancreas | Various | Protection of CSCs against toxicity | Jinushi et al., 2011; Mitchem et al., 2013 |
| Tumor | Drug | Mechanism | Reference |
| Mammary, carcinoma | PTX | CSF1-dependent increased recruitment of TAMs | DeNardo et al., 2011 |
| Mammary, carcinoma | PTX, doxorubicin, etoposide | Increased protease activity | Shree et al., 2011 |
| Cervical, carcinoma | Platinum | Protumor polarization of TAMs | Dijkgraaf et al., 2013 |
| EL-4 lymphoma and other transplanted solid tumors | Gemcitabine + 5-FU | Skewed Th17 response | Bruchard et al., 2013 |
| Pancreatic, carcinoma | Gemcitabine | Induction of drug-metabolizing enzyme | Weizman et al., 2014 |
| Lung, colon, pancreas | Various | Protection of CSCs against toxicity | Jinushi et al., 2011; Mitchem et al., 2013 |